172 related articles for article (PubMed ID: 31324954)
21. Bisphosphonates induce apoptosis in human breast cancer cell lines.
Senaratne SG; Pirianov G; Mansi JL; Arnett TR; Colston KW
Br J Cancer; 2000 Apr; 82(8):1459-68. PubMed ID: 10780527
[TBL] [Abstract][Full Text] [Related]
22. Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells.
Iguchi T; Miyakawa Y; Saito K; Nakabayashi C; Nakanishi M; Saya H; Ikeda Y; Kizaki M
Int J Oncol; 2007 Aug; 31(2):285-91. PubMed ID: 17611684
[TBL] [Abstract][Full Text] [Related]
23. Effects of two novel bisphosphonates on bone cells in vitro.
Evans CE; Braidman IP
Bone Miner; 1994 Aug; 26(2):95-107. PubMed ID: 7994190
[TBL] [Abstract][Full Text] [Related]
24. Zoledronate induces apoptosis in cells from fibro-cellular membrane of unicameral bone cyst (UBC).
Yu J; Chang SS; Suratwala S; Chung WS; Abdelmessieh P; Lee HJ; Yang J; Lee FY
J Orthop Res; 2005 Sep; 23(5):1004-12. PubMed ID: 15921873
[TBL] [Abstract][Full Text] [Related]
25. Dose-dependent metabolic effect of zoledronate on primary human osteoblastic cell cultures.
Corrado A; Neve A; Maruotti N; Gaudio A; Marucci A; Cantatore FP
Clin Exp Rheumatol; 2010; 28(6):873-9. PubMed ID: 21205463
[TBL] [Abstract][Full Text] [Related]
26. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.
Mundy GR; Yoneda T; Hiraga T
Semin Oncol; 2001 Apr; 28(2 Suppl 6):35-44. PubMed ID: 11346863
[TBL] [Abstract][Full Text] [Related]
27. The impact of bisphosphonates on the osteoblast proliferation and Collagen gene expression in vitro.
Koch FP; Yekta SS; Merkel C; Ziebart T; Smeets R
Head Face Med; 2010 Jul; 6():12. PubMed ID: 20618968
[TBL] [Abstract][Full Text] [Related]
28. Activation of BK(Ca) channels in zoledronic acid-induced apoptosis of MDA-MB-231 breast cancer cells.
Ma YG; Liu WC; Dong S; Du C; Wang XJ; Li JS; Xie XP; Wu L; Ma DC; Yu ZB; Xie MJ
PLoS One; 2012; 7(5):e37451. PubMed ID: 22655048
[TBL] [Abstract][Full Text] [Related]
29. Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo.
Wakchoure S; Merrell MA; Aldrich W; Millender-Swain T; Harris KW; Triozzi P; Selander KS
Clin Cancer Res; 2006 May; 12(9):2862-8. PubMed ID: 16675582
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of osteoblast function in vitro by aminobisphosphonates.
Orriss IR; Key ML; Colston KW; Arnett TR
J Cell Biochem; 2009 Jan; 106(1):109-18. PubMed ID: 19003973
[TBL] [Abstract][Full Text] [Related]
31. Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth.
Tauro M; Shay G; Sansil SS; Laghezza A; Tortorella P; Neuger AM; Soliman H; Lynch CC
Mol Cancer Ther; 2017 Mar; 16(3):494-505. PubMed ID: 28069877
[TBL] [Abstract][Full Text] [Related]
32. Zoledronate inhibits the proliferation, adhesion and migration of vascular smooth muscle cells.
Wu L; Zhu L; Shi WH; Zhang J; Ma D; Yu B
Eur J Pharmacol; 2009 Jan; 602(1):124-31. PubMed ID: 19000670
[TBL] [Abstract][Full Text] [Related]
33. Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells.
Ebert R; Meissner-Weigl J; Zeck S; Määttä J; Auriola S; Coimbra de Sousa S; Mentrup B; Graser S; Rachner TD; Hofbauer LC; Jakob F
Mol Cancer; 2014 Dec; 13():265. PubMed ID: 25496233
[TBL] [Abstract][Full Text] [Related]
34. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
Dedes PG; Kanakis I; Gialeli Ch; Theocharis AD; Tsegenidis T; Kletsas D; Tzanakakis GN; Karamanos NK
Biochim Biophys Acta; 2013 Jun; 1830(6):3625-34. PubMed ID: 23395844
[TBL] [Abstract][Full Text] [Related]
35. Differential effects of bisphosphonates on breast cancer cell lines.
Verdijk R; Franke HR; Wolbers F; Vermes I
Cancer Lett; 2007 Feb; 246(1-2):308-12. PubMed ID: 16621245
[TBL] [Abstract][Full Text] [Related]
36. In vitro toxicity of bisphosphonates on human neuroblastoma cell lines.
Vorotnjak M; Boos J; Lanvers-Kaminsky C
Anticancer Drugs; 2004 Sep; 15(8):795-802. PubMed ID: 15494642
[TBL] [Abstract][Full Text] [Related]
37. Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.
Journe F; Chaboteaux C; Magne N; Duvillier H; Laurent G; Body JJ
Breast Cancer Res; 2006; 8(1):R2. PubMed ID: 16417650
[TBL] [Abstract][Full Text] [Related]
38. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
[TBL] [Abstract][Full Text] [Related]
39. The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.
Morgan C; Lewis PD; Jones RM; Bertelli G; Thomas GA; Leonard RC
Acta Oncol; 2007; 46(5):669-77. PubMed ID: 17562444
[TBL] [Abstract][Full Text] [Related]
40. Dickkopf-1 is regulated by the mevalonate pathway in breast cancer.
Rachner TD; Göbel A; Thiele S; Rauner M; Benad-Mehner P; Hadji P; Bauer T; Muders MH; Baretton GB; Jakob F; Ebert R; Bornhäuser M; Schem C; Hofbauer LC
Breast Cancer Res; 2014 Feb; 16(1):R20. PubMed ID: 24528599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
